Early HRT Cuts Fracture Risk 13%: 137K-Woman Study
6/9/2026
5 min read
By The TRT Catalog
A 137,484-woman propensity-matched study found women who started HRT within a year of menopause had lower osteoporosis and fracture risk. What it means.
Key Takeaways: A new propensity-matched study of 137,484 postmenopausal women under 60, presented at the 2026 American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting, found that women who started hormone therapy within one year of their menopause diagnosis had a significantly lower risk of osteoporosis and, over time, fewer fractures. The fracture gap widened with follow-up: no difference at 3 years, 6% higher risk in the non-HRT group at 5 years, and 13% higher at maximum follow-up. It is one of the largest real-world datasets on the question, and it lands at a moment when HRT use has fallen to historic lows and the FDA has moved to drop the old black-box warnings. The honest read: early HRT is a strong bone-protection tool for the right women started at the right time -- but it is prevention, not a rescue for bone already lost, and it belongs in an individualized risk-benefit conversation backed by a DEXA scan and proper monitoring.
What the Study Found
Researchers at Stony Brook University, led by orthopaedic surgeon James Barsi, MD, used the TriNetX research network -- a large multi-institution electronic health record database -- to identify 137,484 postmenopausal women under age 60. They split them into two groups: women who started hormone therapy within one year of their menopause diagnosis ("early HRT"), and matched women who did not. The study, titled Early Hormone Replacement Therapy and Long-Term Bone Health in Postmenopausal Women: A Real-World Propensity-Matched Study, followed both groups for five years.
Two findings drove the headlines:
1. Less osteoporosis in the early-HRT group. Over follow-up, the women who did not start early HRT had a significantly higher risk of being diagnosed with osteoporosis (odds ratio 1.18, 95% CI 1.09–1.28, p < 0.0001). In plain terms, starting hormone therapy early was associated with measurably better preservation of bone density.
2. Fewer fractures -- but only over time. Fracture risk did not differ between the groups at 3 years (relative risk 1.02). By 5 years, the non-HRT group had a 6% higher fracture risk (RR 1.06). At maximum follow-up, that gap widened to 13% higher (RR 1.13). The fracture benefit of early HRT was real but slow to surface.
Women's HRT — Menopause-First Telehealth
Bioidentical estradiol, progesterone, and low-dose testosterone — all 50 states, unlimited physician access.
The strength here is the size and uniformity of the cohort. "The data from this study is particularly meaningful because of the large number and uniformity of participants," Barsi said, "and we hope it leads to more doctors having conversations with eligible patients about HRT as an option." Because it used propensity-score matching rather than randomization, the two groups were balanced on measurable characteristics -- though, as with any observational study, unmeasured differences between women who choose HRT and those who do not can still influence results.
Why the Fracture Gap Took Years to Appear
The timeline in this study is not a flaw -- it is the biology of bone. Estrogen restrains the cells that break bone down (osteoclasts). When estrogen falls at menopause, bone breakdown outpaces bone formation, and women can lose up to 20% of their bone density in the 5 to 7 years after menopause. That is the fastest loss of a woman's life.
But a fracture is a downstream event. It takes years of accumulated density loss before bones get thin enough that they actually break. So a therapy that prevents loss during the rapid early window protects the bone immediately, but the visible payoff -- fewer broken hips, wrists, and spines -- only shows up later, once the untreated group has had time to thin into fracture territory. That is precisely the staircase this study captured: nothing at 3 years, 6% at 5 years, 13% at maximum follow-up.
The practical implication is about timing. The benefit comes from protecting bone before it is lost, which is why "early" -- within a year of menopause in this dataset -- matters so much. This dovetails with the broader timing hypothesis for when to start HRT: the window where hormone therapy's benefits concentrate is the years right around the menopause transition.
How This Fits the Bigger Picture
This is not the first evidence that estrogen protects bone -- it is some of the largest. Earlier data had already established that HRT cuts fracture risk substantially; our HRT and bone density guide walks through the mechanism and the DEXA-scan timing. What this Stony Brook analysis adds is a very large, modern, real-world cohort confirming the effect and showing the early-start gradient over time.
What makes the finding newsworthy is the context it lands in. HRT use among women 40 and older has fallen to historic lows -- down to roughly 1.7% by 2023 per a recent Mayo Clinic Proceedings analysis, even among the women most likely to benefit. We covered that collapse in HRT use and the barriers driving women away from menopause care. Meanwhile, the FDA has moved to remove the old black-box warnings that scared a generation of women and clinicians off hormone therapy. So this study arrives as a fresh, large data point on one side of a widening gap: the evidence for benefit in well-selected women keeps growing, while actual use sits near rock bottom.
What This Does -- and Does Not -- Mean for You
A few honest guardrails:
It is prevention, not rescue. Early HRT preserves bone you still have. If you already have osteoporosis on a DEXA scan, HRT may be part of the plan, but bone-specific drugs are often added. Get a baseline DEXA around the menopause transition so you know where you actually stand.
"Early" is a gradient, not a hard deadline. The one-year window defined the study's early group, but the underlying message is sooner is better relative to your last period -- not that HRT is useless if you missed a 12-month cutoff.
Bone is one input, not the whole decision. HRT's full risk-benefit picture includes hot flashes, sleep, genitourinary symptoms, cardiovascular timing, and a small, regimen-dependent breast cancer consideration. Bone protection is a strong point in favor for the right woman, not the only factor.
Monitoring matters. Bone-protective HRT means an appropriate estradiol dose (with a progestogen if you have a uterus), baseline and follow-up labs, and a DEXA strategy -- not a fixed starter dose mailed out with no follow-up.
That last point is why where you get care shapes what you get out of it. A menopause-literate provider that does real labs, dose titration, and DEXA coordination is a different product from a one-size-fits-all script. If you are weighing HRT for bone protection, our women's HRT clinic comparison and the full clinic comparison and scores break down which providers offer proper monitoring, physician oversight, and transparent pricing -- and our guide on how to choose a clinic covers the questions to ask before you commit.
References
Barsi J, et al. Early Hormone Replacement Therapy and Long-Term Bone Health in Postmenopausal Women: A Real-World Propensity-Matched Study. Presented at the 2026 American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting. AAOS 2026 Annual Meeting Press Kit
Medscape. Early Hormone Replacement Therapy Linked to Lower Osteoporosis Risk in Postmenopausal Women (2026). medscape.com
U.S. FDA. HHS Advances Women's Health, Removes Misleading FDA Warnings on Hormone Replacement Therapy.fda.gov
What did the Stony Brook early-HRT bone study actually find?
Stony Brook University researchers, led by orthopaedic surgeon James Barsi, MD, used the TriNetX research network to analyze 137,484 postmenopausal women under age 60, comparing those who started hormone therapy within one year of their menopause diagnosis (early HRT) against matched women who did not. The early-HRT group had a significantly lower risk of developing osteoporosis (odds ratio 1.18 in favor of the non-HRT group having more osteoporosis, p < 0.0001). Fracture risk diverged over time: there was no significant difference at 3 years, but by 5 years the non-HRT group had 6% higher fracture risk, and at maximum follow-up they had 13% higher risk. The findings were presented at the 2026 American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting.
Why did the fracture difference only show up after 3 years?
Bone loss after menopause is fast but fractures are a downstream event -- it takes years of accumulated bone-density loss before that translates into measurably more broken bones. Women lose the most bone density in the first 5 to 7 years after menopause, so a protective therapy started early prevents loss during that critical window, but the payoff in fewer fractures shows up later, once the untreated group has had time to thin enough that they actually start breaking bones. That is exactly the pattern this study captured: no fracture gap at 3 years, a 6% gap at 5 years, and a 13% gap at maximum follow-up. It is an argument for starting early and staying on, not for expecting an overnight effect.
Does 'early HRT' mean I have to start the moment I hit menopause?
In this study, early HRT was defined as starting within one year of the menopause diagnosis, and that is the group that benefited. It lines up with the broader timing-hypothesis evidence that starting hormone therapy within about 10 years of menopause (or before age 60) is where the favorable bone, cardiovascular, and mortality signals concentrate. The practical message is not that there is a hard one-year cutoff after which HRT is useless -- it is that the earlier you start relative to your last period, the more of the rapid early bone loss you prevent. If you are within a few years of menopause and have bone-loss risk factors, that is a conversation to have with a clinician now rather than later.
Is HRT a substitute for a DEXA scan or osteoporosis medication?
No. HRT is a prevention tool that works best before significant bone loss has happened; it is not a replacement for diagnosis or for dedicated osteoporosis drugs once you already have low bone density. A DEXA (bone density) scan is how you find out where you actually stand -- baseline around the menopause transition, then repeated as your clinician advises. If a DEXA already shows osteoporosis, HRT may still be part of the plan but bone-specific medications (bisphosphonates and others) are often added. Think of early HRT as keeping the bone you have, and DEXA plus osteoporosis drugs as the response when bone is already lost.
Does this study mean HRT is safe -- what about breast cancer?
This study was about bone outcomes, not overall safety, so it does not by itself settle the risk-benefit question. That said, it lands in a 2026 climate where the FDA has moved to remove the old black-box warnings from menopausal hormone therapy and where large analyses keep finding the historical fears were overstated for women who start near menopause. Breast cancer risk with combined estrogen-plus-progestogen HRT is real but small and depends on the regimen, duration, and your personal history. The right move is an individualized risk-benefit discussion with a clinician who treats menopause regularly, not a blanket yes or no -- which is also why where you get care matters.
Where can I get HRT prescribed and monitored for bone protection?
Bone-protective HRT requires more than a one-time prescription -- you want baseline labs, a DEXA scan to establish where your bone density starts, an appropriate estradiol dose (with a progestogen if you have a uterus), and follow-up. Many women get this through a menopause-focused telehealth clinic or an in-person menopause specialist. The key is choosing a provider that does real monitoring and dose titration rather than shipping a fixed starter dose with no follow-up. Our women's HRT clinic comparison breaks down which providers offer proper labs, physician oversight, and transparent pricing.
